Table 2.

Summary of the tracer discussed in this review with the corresponding targets as well as their current status

Target	Imaging agent	Current status	References
VMAT2	[11C]DTBZ	Preclinical studies (in vitro and in vivo in rats)	[19]
	[18F]FE-DTBZ d4	Preclinical studies (in vitro and in vivo in pigs)	[20]
	[18F]-FP-(+)-DTBZ	Clinical studies	[21–23]
SUR1	18F and 99mTc labeled glibenclamide derivatives	Clinical studies	[24]
	99mTc-DTPA-glipizide	Preclinical studies (in vitro and in vivo in mice)	[25]
Sphingomyelin patches on the β-cell surface	111In-DTPA-IC2	Preclinical studies (in vitro and in vivo in mice)	[26, 27]
β-cell-surface epitopes	125I-labeled SCA B1, SCA B2, SCA B3, and SCA B4; SCA B2 functionalized carbon-coated cobalt NP	Preclinical studies (in vitro and in vivo in mice and rats)	[28, 29]
hTMEM27	AF 488 / [89Zr]-8/9-mAb	Preclinical studies (in vitro and in vivo in mice)	[30]
Glucose transporter	18F-FDG,	Clinical studies	[31, 32]
LAT	18F-DOPA, [11C]-5-HTP	Clinical studies	[33–37]
D2 receptor	[18F]-fallypride	Preclinical studies (in vitro and in vivo in rats)	[38–40]
Zn2+release	GdDOTA-diBPEN	Preclinical studies (in vitro and in vivo in mice)	[41–43]
Voltage-gated Ca2+ Ca2+ channels	Mn2+	Preclinical studies (in vitro and in vivo in mice), retrospective study in humans	[44–47]
Unclear	PiY	Preclinical studies (in vitro and ex vivo analysis of mouse organs)	[48]